We are Atlantic Therapeutics, a medical device developer on a mission to help millions of people restore their pelvic floor and treat Urinary Incontinence, giving them the confidence and control they need to live an active life.
We develop and manufacture medical device-quality pelvic floor muscle strengthening products — all backed by strong clinical evidence and subjected to controlled trials. We are at the leading edge of technological developments in muscle rehabilitation and conditioning, pioneering clinically proven pelvic floor health solutions.
Thousands of healthcare providers and customers across the world rely on Atlantic Therapeutics product 'INNOVO' to improve the lives of those with pelvic floor issues. We continue to pursue rigorous clinical trials to further the use of INNOVO to treat bladder weakness.
Since launching in the European market of March 2016, INNOVO has become the leading choice for a safe, effective, home-based treatment targeting the causes — not just the symptoms of Urinary Incontinence. INNOVO is currently available in the United States, UK, France, Germany, Ireland and the Middle East, with more launches planned for the near future. In the United States, INNOVO is FDA cleared to treat stress urinary incontinence in women.
What is INNOVO?
Easy to use, comfortable to wear, and clinically proven to work, INNOVO is a completely non-invasive solution that helps you safely and effortlessly treat bladder weakness by strengthening and re-educating the entire network of pelvic floor muscles through gentle muscle stimulation.
Using INNOVO for just 30 minutes a day/five days a week over 12 weeks has been proven to treat bladder weakness – delivering results in as little as four weeks1.
INNOVO treats Stress, Urge & Mixed Incontinence in both women and men of all ages, and is the only non-invasive pelvic floor exerciser that targets the root cause of the problem.
of users saw a significant improvement after 4 weeks1
of users saw were defined as dry or near dry after 12 weeks2
of users would recommend the therapy to others3
The INNOVO Story with co-inventor Dr. Ruth Maher & OB/GYN Dr. Sherry Ross
Who is affected by bladder weakness?
FDA Grants DeNovo Clearance to Atlantic Therapeutics for INNOVO Therapy Device to Treat Stress Urinary Incontinence
We're excited to announce that the U.S. Food and Drug Administration (FDA) has granted a DeNovo clearance for the INNOVO therapy device, an externally worn electrical muscle stimulator for the treatment of stress urinary incontinence in adult females.READ MORE
A non-invasive, clinically proven therapy
All you need to know about the pelvic floor
What is INNOVO, how does it work, and why do you need it if you’re trying to overcome bladder weakness once and for all? Our short video explains everything.
Atlantic Therapeutics is proud to work with knowledgeable, driven partners to give us the best possible understanding of local market needs and to provide our customers with the highest possible level of service.
For information about how you can access Innovotherapy in your country, please contact us.
If you are interested in joining Atlantic Therapeutics’ distribution network as we introduce our clinically proven, safe and effective treatment globally, please contact us through firstname.lastname@example.org.
We know that bladder weakness is a difficult subject to bring up, so at Atlantic Therapeutics we’re keen to support and reward ambassadors who are open to discussing and promoting a clinically proven solution that will help to improve their customers’ quality of life. Contact us today to find out how you can join Atlantic Therapeutics growing network of Innovotherapy Ambassadors.
Atlantic Therapeutics develops professional and consumer medical devices, related software, apps and connected health technologies to treat all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor. All Atlantic Therapeutics Group Ltd. products are certified under the European Medical Devices Directive 93/42/EEC.
Atlantic Therapeutics Group Ltd, has recently successfully completed a €15 million growth capital financing, enabling the company to move forward with the next phase of growth and treat millions of people across the globe who suffer from bladder weakness, clinically known as stress urinary incontinence.
The funds come from a combination of venture capital investment from Seroba Life Sciences and Earlybird Venture Capital, as well as Bio-medical Research Group Ltd (previous owner) which retains a minority shareholding. The capital enables Atlantic Therapeutics to accelerate growth from INNOVO technology platform via market and geographic expansion and new product development.
Board of Directors
Mr Gordie Nye, Chairman of the Board
Mr Steve Atkinson, Chief Executive Officer
Dr Daniel O’Mahony, Seroba Life Sciences
Anne Portwich, LSP
Thom Rasche, Earlybird Venture Capital
Aneta Sottil, Andera Partners
Paul Murray, Atlantic Bridge Ventures
Dr Bernard Collins, Biomedical Research
Mary Ann Pesce, Non-Executive Director, Boston
Clinical Advisory Board Members
Professor Roger Dmochowski – Urologist, Director of Female Pelvic Medicine, Vanderbilt, USA
Professor Ralf Tunn - Urogynaecologist, Berlin. Coordinator of German Pelvic Floor Centres
Professor Linda Cardozo - Urogynaecologist, King’s College Hospital, London
Professor Ruth Maher - Creighton University. One of the inventing clinicians
Professor François Haab – Urologist, Paris Opéra
Dr Guillermo Davila - Obstetrician-Gynaecologist, Head of Pelvic Floor Reconstructive Surgery, Cleveland Clinic, USA
Dr Peter Sand - Urologist, Evanston Chicago, USA
Dr Michael Gambla - Columbus, Large Urology Group Practices, USA
Dr Sherry Ross - Obstetric-Gynaecologist, Los Angeles, USA.
Mr Ash Monga – Urogynaecologist specialising in conditions of the Pelvic Floor, University of Southampton
Sonia Söder – Lead Physical Therapist, Berlin Pelvic Floor Centre